Use of sialyltransferase inhibitor in preparing medicament for neutralizing acidic tumor microenvironment
By using a combination of sialic acid transferase inhibitors and PD-1 drugs to neutralize the acid tumor microenvironment, the problems of tumor metastasis and immunosuppression in Brca1-related breast cancer were solved, and the establishment and treatment effects of tumor ecological barrier were achieved.
Patent Information
- Application Number
- PCT/CN2023/128090
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-09
- Filing Date
- 2023-10-31
- Publication Date
- 2024-11-14
AI Technical Summary
The prior art is difficult to effectively neutralize the acidic tumor microenvironment, resulting in cancer cell metastasis and immunosuppression, especially in Brca1-related breast cancers, where effective treatments are lacking.
Using sialic acid transferase inhibitors, such as 3Fax-Peracetyl Neu5Ac or Stattic, by inhibiting polysialic transferase and its receptors, binding to PD-1 drugs, neutralizing the acid tumor microenvironment, blocking the Vegfa/Il6 signaling pathway, reducing the TGF-β signaling reduces the activity of MDSCs and restores the bilayer structure integrity of the breast epithelial.
Effectively neutralize the acid tumor microenvironment, inhibit tumor growth and metastasis, enhance immune cell activity, improve sensitivity to αPD-1 treatment, reduce the risk of tumor metastasis, and provide new ways to treat Brca1 defect-related breast cancer.
Smart Images

Figure CN2023128090_14112024_PF_FP_ABST
Abstract
Description
Application of sialyltransferase inhibitors in the preparation of drugs for neutralizing the acidic tumor microenvironment
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims priority to Chinese patent application No. 2023105179746 filed with the State Intellectual Property Office of China on May 9, 2023, entitled “Application of sialyltransferase inhibitors in the preparation of drugs for neutralizing acidic tumor microenvironment”, the entire contents of which are incorporated by reference into this application. Technical Field
[0003] The present disclosure relates to the technical field of tumor treatment, and in particular, to the use of a sialyltransferase inhibitor in the preparation of a drug for neutralizing an acidic tumor microenvironment. Background Art
[0004] Cancer metastasis is an extremely complex process that is influenced by many factors, including the production of lactate / H2O, which is generally considered to be mainly produced by glycolysis. + Acidity is one of the main characteristics of many cancers. It is currently believed that acidity is caused by the accumulation of metabolic waste caused by cancer cells with high metabolic activity and insufficient blood perfusion. During tumor growth and metastasis, the acidic tumor microenvironment (ATME) is believed to be caused by the lactic acid / H produced by glycolysis. + , bicarbonate and CO 2 The protons and H produced by hydrogenation + This is caused by the removal of cytosol from the interstitial space. The pH of the acidic tumor microenvironment (ATME) is generally 5.6-7.0. This acidic microenvironment not only facilitates the migration of cancer cells through the extracellular matrix (ECM) to blood vessels with a relatively high pH (7.35-7.45), but also hinders the infiltration of active immune cells into tumor tissues by reducing the activity of T cells and NK cells, thereby achieving tumor metastasis. To date, no other mechanism that can cause the generation of an acidic tumor microenvironment (ATPME) has been discovered.
[0005] According to surveys, breast cancer has the highest incidence rate of all cancers, with 2.26 million new cases of breast cancer and approximately 685,000 cancer deaths in 2020. Almost all breast cancers originate from mammary epithelial cells, which are arranged in a double-layer structure between the lobules and terminal ducts. The inner layer contains secretory luminal epithelial cells, and the outer layer is composed of contractile myoepithelial cells (or basal cells) surrounded by a basement membrane (BM). The integrity of the epithelial bilayer is important for maintaining normal development of the mammary gland and preventing malignant transformation of epithelial cells. In addition, the spread of malignant cells to secondary organs depends on their ability to destroy the basement membrane and basal layer, which mainly contain laminin and collagen IV, their ability to invade the extracellular matrix, infiltrate the circulation, extravasate from blood vessels, and grow in distant organs. Therefore, the study of tumor growth and metastasis plays a key role in the treatment and prevention of cancer.
[0006] In view of this, the present disclosure is proposed.
[0007] Summary of the Invention
[0008] The present disclosure provides a use of a sialyltransferase inhibitor in the preparation of a medicament for neutralizing an acidic tumor microenvironment.
[0009] Optionally, the sialyltransferase inhibitor neutralizes the acidic tumor microenvironment by downregulating the expression of Vegfa and / or VegfIl6.
[0010] Optionally, the sialyltransferase inhibitor comprises at least one of 3Fax-Peracetyl Neu5Ac or Stattic.
[0011] Optionally, the sialyltransferase inhibitor inhibits the expression of polysialyltransferase and / or polysialyltransferase receptor.
[0012] Optionally, the polysialyltransferase comprises St8sia4.
[0013] Optionally, the polysialyltransferase receptor includes at least one of soluble E-selectin and L-selectin.
[0014] Optionally, the drug for neutralizing the acidic tumor microenvironment also includes a PD-1 drug; optionally, the PD-1 drug is a PD-1 antibody.
[0015] The present disclosure provides a use of a sialyltransferase inhibitor in preparing a medicament for treating Brca1 deficiency-related tumors.
[0016] Optionally, the drug for treating Brca1 deficiency-related tumors also includes a PD-1 drug; optionally, the PD-1 drug is a PD-1 antibody.
[0017] Optionally, the Brca1 deficiency-related tumor is Brca1 deficiency-related breast cancer.
[0018] The present disclosure provides a use of a sialyltransferase inhibitor in the preparation of a drug for preventing or treating cancer. The drug for preventing or treating cancer includes drugs for preventing or treating any one of the occurrence, metastasis or growth of cancer.
[0019] Optionally, the drug for preventing or treating cancer also includes a PD-1 drug; optionally, the PD-1 drug is a PD-1 antibody.
[0020] Optionally, the cancer includes any one of breast cancer, liver cancer, and spleen cancer.
[0021] The present disclosure provides use of a sialyltransferase inhibitor in preparing a drug for treating destruction of the double-layer structure of mammary epithelium.
[0022] Optionally, the drug for treating destruction of the double-layer structure of mammary epithelium also includes a PD-1 drug; optionally, the PD-1 drug is a PD-1 antibody.
[0023] The present disclosure provides a pharmaceutical composition comprising the aforementioned sialyltransferase inhibitor and pharmaceutically acceptable excipients.
[0024] Optionally, the sialyltransferase inhibitor comprises at least one of 3Fax-Peracetyl Neu5Ac or Stattic.
[0025] Optionally, the dosage form of the drug includes any one of injection, injection, tablet, granule, granule or capsule.
[0026] Optionally, the drug is in the form of nanoparticles.
[0027] The present disclosure provides a method for neutralizing an acidic tumor microenvironment, comprising administering to a subject in need thereof an effective amount of a sialyltransferase inhibitor.
[0028] The present disclosure provides a method for treating a tumor associated with Brca1 deficiency, the method comprising administering to a subject in need thereof an effective amount of a sialyltransferase inhibitor;
[0029] Optionally, the Brca1 deficiency-related tumor is Brca1 deficiency-related breast cancer.
[0030] The present disclosure provides a method for preventing or treating cancer, comprising administering an effective amount of a sialyltransferase inhibitor to a subject in need thereof; wherein the drug for preventing or treating cancer includes drugs for preventing or treating any one of the occurrence, metastasis or growth of cancer.
[0031] Optionally, the cancer includes any one of breast cancer, liver cancer, and spleen cancer.
[0032] The present disclosure provides a method for treating disruption of the bilayer structure of mammary epithelium, comprising administering an effective amount of a sialyltransferase inhibitor to a subject in need thereof.
[0033] Optionally, the sialyltransferase inhibitor comprises at least one of 3Fax-Peracetyl Neu5Ac or Stattic.
[0034] Optionally, the above method comprises the combined use of a PD-1 drug; optionally, the PD-1 drug is a PD-1 antibody.
[0035] The present disclosure provides a sialyltransferase inhibitor for the following uses:
[0036] i. Neutralize the acidic tumor microenvironment;
[0037] ii. Treating Brca1 deficiency-associated tumors; optionally, the Brca1 deficiency-associated tumor is Brca1 deficiency-associated breast cancer;
[0038] iii. Preventing or treating cancer; wherein preventing or treating cancer includes preventing or treating any one of the occurrence, metastasis or growth of cancer; optionally, the cancer includes any one of breast cancer, liver cancer, and spleen cancer;
[0039] iv. Treat the destruction of the double-layer structure of mammary epithelium.
[0040] Optionally, the sialyltransferase inhibitor comprises at least one of 3Fax-Peracetyl Neu5Ac or Stattic.
[0041] Optionally, the use includes a sialyltransferase inhibitor combined with a PD-1 drug; optionally, the PD-1 drug is a PD-1 antibody. BRIEF DESCRIPTION OF THE DRAWINGS
[0042] In order to more clearly illustrate the technical solutions of the embodiments of the present disclosure, the following briefly introduces the drawings required for use in the embodiments. It should be understood that the following drawings only illustrate certain embodiments of the present disclosure and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other relevant drawings can be obtained based on these drawings without creative work.
[0043] FIG1 shows the results of the destruction of the mammary double-layer structure associated with elevated sialyltransferase provided by the embodiments of the present disclosure;
[0044] FIG2 is a graph showing the results of elevated sialyltransferase in mouse mammary tissue according to an embodiment of the present disclosure;
[0045] FIG3 is a graph showing the increase in polysialic acid content in mouse Brca1-deficient cells and human Brca1-deficient breast cancer samples provided by the embodiments of the present disclosure;
[0046] FIG4 is a diagram showing changes in sialyltransferases in Brca1-deficient mice and non-Brca1-deficient mice according to an embodiment of the present disclosure;
[0047] FIG5 is a diagram showing the effect of sialyltransferase on breast cancer metastasis provided by an embodiment of the present disclosure;
[0048] FIG6 is a diagram showing the effect of sialyltransferase expression on tumor growth and metastasis provided in an embodiment of the present disclosure;
[0049] FIG7 is a diagram showing the detection results of the expression process of sialyltransferase in mammary epithelial cells provided by an embodiment of the present disclosure;
[0050] FIG8 shows that the Vegfa / Il6 signaling pathway upregulates TGF-β signaling in Brca1-deficient mammary epithelial cells and macrophages according to an embodiment of the present disclosure;
[0051] FIG9 shows the results of the tumor immunosuppressive microenvironment induced by hypersialylation in breast tissues of mice and human breast cancer patients provided by the embodiments of the present disclosure;
[0052] FIG10 is a diagram showing the relationship between the increase in the number of MDSCs in Brca1-deficient mice and the effect of Vegfa / Il6 provided in an embodiment of the present disclosure;
[0053] FIG11 shows the results of inhibiting breast tumor growth and metastasis using sialyltransferase inhibitors and their combination with drugs provided in the examples of the present disclosure;
[0054] FIG12 shows the results of inhibiting breast tumor growth and metastasis after intraperitoneal injection of sialyltransferase inhibitors and drugs used in combination therewith provided in the embodiments of the present disclosure;
[0055] FIG13 is a graph showing the results of treating breast tumors with high sialyltransferase expression using a sialyltransferase inhibitor in combination with αPD-1 according to an embodiment of the present disclosure;
[0056] FIG14 shows the effects of the sialyltransferase inhibitor provided in the embodiments of the present disclosure in combination with αPD-1 on different cells during breast tumor growth and metastasis. DETAILED DESCRIPTION
[0057] To make the purpose, technical solutions, and advantages of the embodiments of the present disclosure more clear, the technical solutions in the embodiments of the present disclosure are described clearly and completely below. Where specific conditions are not specified in the embodiments, conventional conditions or conditions recommended by the manufacturer were followed. Reagents or instruments used where the manufacturer is not specified are conventional products that can be purchased commercially.
[0058] The features and performance of the present disclosure are further described in detail below with reference to the embodiments.
[0059] The term "Brca1" stands for breast cancer associated gene 1, a tumor suppressor gene whose germline mutations cause familial breast cancer.
[0060] The term "EMT" stands for epithelial-mesenchymal transition, which refers to the transformation of epithelial cells to mesenchymal cells. It confers the ability of cells to metastasize and invade, including stem cell characteristics, reduces apoptosis and aging, and promotes immunosuppression. It not only plays a key role in the development process, but also participates in processes such as tissue healing, organ fibrosis and cancer occurrence.
[0061] The term "MDSCs" refers to myeloid-derived suppressor cells, which are precursors of dendritic cells, macrophages and / or granulocytes and have the ability to significantly suppress immune cell responses.
[0062] The term "ATPME" refers to acidic tumor microenvironment.
[0063] The terms "Vegfa" and "VegfIL6" are both transcriptional regulators involved in angiogenesis and tumor cell invasion, where Vegfa is vascular endothelial growth factor A (VEGF-A).
[0064] VegfIL6 is vascular endothelial growth factor (VEGF) and IL-6, IL-6 is interleukin-6, a cytokine belonging to the chemokine family.
[0065] The sialyltransferase genes St8sia4 and St3gal1 are responsible for the production of polysialic acid (PSA) and Sialyl-Lewis A (sLeA), respectively.
[0066] 3Fax-Peracetyl Neu5Ac, molecular formula: C 22 H 30 FNO 14 , the structural formula is as follows:
[0067] As a cell-permeable silyl analog, 3Fax-Peracetyl Neu5Ac can be converted to CMP-Neu5Ac and inhibit silyltransferase. In this application, it is used as a sialyltransferase inhibitor.
[0068] Stattic is a STAT3 inhibitor with a molecular formula of C8H5NO4S and a structural formula as shown below:
[0069] The present disclosure provides a sialyltransferase inhibitor for use in the preparation of a drug for neutralizing the acidic tumor microenvironment. Research has found that sialyltransferase inhibitors can neutralize the acidic tumor microenvironment and establish an ecological barrier to tumor metastasis, providing a new approach for the prevention and treatment of tumors.
[0070] The sources of the human tissue microarrays and human breast cancer samples used in the following experiments are as follows: 95 human breast cancer tissue microarray samples were kindly provided by the Third Affiliated Hospital of Sun Yat-sen University. Twenty-five human breast cancer samples for immunofluorescence staining were kindly provided by the First Affiliated Hospital of Sun Yat-sen University and sequenced for BRCA mutations. Of these 25 primary tumor samples, 4 were BRCA1 mutation carriers and 21 were non-BRCA1 mutation carriers. Human tissues were formalin-fixed, paraffin-embedded, and sectioned for use in experiments.
[0071] The sources of mice and experimental cell lines used in the following experiments are as follows: All mouse experiments performed in this study were approved by the Animal Ethics Committee of the University of Macau.
[0072] The Brca1 conditional knockout mouse model (Brca1co / co; MMTV-Cre) has been established in the inventors' laboratory.
[0073] To establish a tumor allograft model, Brca1WT (B477) mammary epithelial cells (2×10 5 ) and Brca1-MT (G600) mammary epithelial cells (2×10 5 ) were orthotopically implanted into the fourth mammary fat pad of the right side of 5-6 week-old nude mice. To establish a tumor metastasis model, the constructed 545 (Brca1 mutant low metastasis), 628W (Brca1 wild type high metastasis) and EMT6 cells (5×10 5 ) were injected orally into the fourth mammary fat pad on the right side of nude mice and Balb / c mice or directly through the tail vein (5×10 4 The calculation formula for tumor volume is: V = 0.5 × L × W 2 , where L represents the long diameter and W represents the short diameter. For drug treatment experiments, when the tumor volume reaches about 50 mm 3The researchers administered different drugs, including 3Fax-P-Neu5Ac (20 mg / kg), an inhibitor of sialyltransferase, via intraperitoneal injection for seven consecutive days, and Stattic (10 mg / kg), an intraperitoneal injection three times a week. For nanoparticle delivery, Stattic (10 mg / kg) and 3Fax-P-Neu5Ac (20 mg / kg) were administered intravenously once every three days for a total of three times.
[0074] The ratiometric fluorescent probe was kindly provided by Professor Zhang Xuanjun of the University of Macau, and Stattic and 3Fax-P-Neu5Ac nanoparticles were kindly provided by Professor Dai Yunlu of the University of Macau. The PD1 antibody, αPD-1 used in the examples of this application, was purchased from Bio X Cell InVivoMab, catalog number: BE0273-5mg.
[0075] The sources of RNA-seq data and human datasets in the following experiments are as follows: bone marrow, blood, spleen, peritoneal cells, and mammary tissues from 10-month-old mice and mammary tumors collected from Brca1co / co tumor mice were isolated in Trizol, and total RNA was subjected to mRNA isolation and library construction, followed by RNA sequencing (Hiseq, paired-end, 6GB raw data per sample). The data were analyzed using HISAT, StringTie, and Ballgown to obtain differentially expressed genes. FPKM values were extracted for each relevant gene to generate a matrix, and heat maps were drawn for different important genes in different organs using RStudio. The immune cell composition in the mammary gland and mammary tumors was calculated by ImmuCC and plotted by heat maps. To predict the correlation between immune cell abundance and St8sia4 expression, the human dataset of BRCA samples was obtained from TISIDB (http: / / cis.hku.hk / TISIDB / index.php). Data on the transcript or protein levels of St8sia4 and St3gal1 genes were obtained from breast cancer patients in the TCGA database, and the graphs were obtained from Linkedomics (http: / / www.linkedomics.org / login.php). Survival curves for breast cancer patients with high or low gene expression were obtained using the Kaplan-Meier plotter (https: / / kmplot.com / analysis / ).
[0076] The sources of immunofluorescence staining of tissue sections in the following experiments are as follows: All human and mouse paraffin slides were dewaxed and rehydrated according to standard protocols. The slides were washed with PBS and then heated in R-Buffer-A (10 mL in 90 mL water). After treatment (or overnight incubation), the slides were washed with PBS and then treated with 0.5% Triton X-100 and 0.5 mg / ml sodium borohydride (in PBS) for 10 minutes at room temperature. The slides were then incubated with blocking solution (50% 3% BSA and 50% Animal-Free Blocker) at room temperature overnight or for at least 1 hour and incubated with primary antibodies from different sources overnight at 4°C. Secondary antibodies and DAPI were incubated for 1 hour at room temperature, anti-fading reagents were applied to the tissues, and coverslips were placed on each slide. Images were scanned using a Carl Zeiss LSM880 super-resolution microscope.
[0077] The following experiments were performed using the following methods for immunofluorescence staining of cells: cells were seeded in a 4-well chamber, washed twice with PBS, and fixed with 4% formaldehyde for 15 minutes. Cells were then washed thoroughly with PBS and treated with 0.5% Triton X-100 for 10 minutes, followed by incubation with blocking solution for at least 1 hour at room temperature. Primary antibodies were incubated overnight at 4°C, and secondary antibodies were incubated for 1 hour at room temperature. Images were scanned using a Carl Zeiss LSM880 super-resolution microscope.
[0078] The cytokine antibody arrays used in the following experiments were prepared as follows: serum from 6-month-old mice and supernatants from various cell lines were diluted in 1× blocking buffer. The diluted samples were added to membranes in a 4-well tray and pre-incubated with 1× blocking buffer for 30 minutes at room temperature and incubated overnight at 4°C. The membranes were placed in a clean container and washed with 20-30 mL of 1× wash buffer I per membrane for 30-45 minutes. They were then returned to the 4-well tray and washed twice with 2 mL of wash buffer II at room temperature. 2 mL of 1× biotin-conjugated anti-cytokines was pipetted into each well, and the membranes were incubated overnight at 4°C. 2 mL of 1× HRP-conjugated streptavidin was added to each well, and the membranes were incubated overnight at 4°C. The membranes were washed and processed the following day as described above. Detection buffer C and detection buffer D were mixed in equal volumes (1:1) and covered with the membranes in the tray. After incubation at room temperature for 2 min, the membrane was immediately exposed, and images were captured using an immunoblot imaging system.
[0079] The following experiments were performed to determine tissue pH: Different cell lines were seeded into 24-well plates at the same initial concentration. After incubation for 48 or 72 hours, the pH of the supernatant from different wells was measured using a cell culture biochemical analyzer. To determine intracellular pH, a ratiometric fluorescent probe was diluted in culture medium (10 μM) and added to the different cultured cells, followed by incubation at 37°C for 1 hour. The cells were washed with PBS in a 4-well confocal chamber, and green and red fluorescence was captured using a Carl Zeiss LSM880 super-resolution microscope. To determine tissue pH, fresh tumor samples were cut into 250 μm sections and stained with a ratiometric fluorescent probe (40 μM) for 1 hour at 37°C, followed by washing with PBS. Images were acquired using a Leica M165FC stereomicroscope. pH was determined according to the formula: (y = 31.8403 - 4.4898x, R = 0.9928, where y represents the pH value and x represents the ratio of red to green fluorescence intensity).
[0080] Protein extraction and immunoblotting in the following experiments were performed using RIPA buffer (150 mM NaCl, 50 mM Tris-HCl, pH 7.4, 10% glycerol, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, and 1 mM EDTA) supplemented with a cocktail of protease inhibitors and phosphatase inhibitors. Membranes with different target proteins were incubated with primary antibodies overnight at 4°C and with secondary antibodies for 1 hour at room temperature. Images were acquired using the ODYSSEYCLx dual-color infrared laser imaging system.
[0081] The methods for RNA extraction and real-time qPCR analysis in the following experiments are as follows: RNA was isolated from fresh breast, tumor, and spleen tissues using Trizol and reverse transcribed using the PrimeScript™ RT kit and gDNA Eraser (Takara #RR047Q). Real-time qPCR was performed using a fluorescent quantitative PCR kit (Roche, 24759100), and data were acquired using a real-time fluorescent quantitative PCR system (ThermoFisher).
[0082] The mass spectrometry analysis method used in the following experiments was as follows: Single cells from adjacent mammary gland tissue and tumor tissue of mouse tumors were collected and digested for 2 hours at 37°C in digestion medium containing 5% fetal bovine serum, 5 μg / ml insulin (I-1882; Sigma-Aldrich), 500 ng / ml hydrocortisone (H0888; Sigma-Aldrich), 300 U / ml collagenase III (S4M7602S, Worthington, Lakewood, NJ), and 100 U / ml hyaluronidase (H3506; Sigma-Aldrich). Cells were then washed with HPSS (14170-112; Life Technologies). Cells were lysed in 1x RBC lysis buffer for 3 minutes at room temperature (RT) to deplete erythrocytes and quenched with HBSS. The suspension was then filtered through a 40 μm cell strainer and washed with PBS. The cells were resuspended in preheated serum-free medium to a density of 2x107 cells / ml, and an equal volume of 10μM cisplatin compound solution was added to the cell suspension (final concentration of cisplatin compound: 5mM). The cells were resuspended and incubated at room temperature for 5 minutes. Then, 5 volumes of Maxpar Cell Staining Buffer were added to quench cisplatin staining, and the cells were centrifuged at 300x g for 5 minutes. The cells were then washed once with 1ml Maxpar Cell Staining Buffer, and 3 million cells were suspended in 80μl Maxpar Cell Staining Buffer. The suspended cells were added to 20μl of Fc blocking solution. The cells were incubated at 4°C for 10 minutes and then resuspended in 50μl Maxpar Cell Staining Buffer. 50μl of antibody mixture was added to each test tube, and the cells were incubated at room temperature for 30 minutes after gentle vortexing. The cells were then washed twice with 1 ml of Maxpar Cell Staining Buffer and 1 ml of cell embedding solution (Cell-ID Intercalator-Ir diluted with Maxpar Fix and Perm Buffer) was added. The sample was mixed thoroughly and placed at 4°C overnight. The next day, the cells were washed twice with 1 ml of Maxpar Cell Staining Buffer and 1 ml of Maxpar water. The cell concentration was adjusted to 2.5-5 x 10 using positive control bead buffer (EQTM Four Element Calibration, Cat. #201078). 5 / ml, and then the data were collected on a mass spectrometry flow instrument (Fluidigm).
[0083] The flow cytometric analysis method used in the following experiments was as follows: Single cells were collected from nude mouse breast tumors, bone marrow, blood, spleen, and peritoneum, then treated with RBC lysis buffer and washed with PBS. The cells were resuspended in 100 μL of PBS and incubated with conjugated antibodies on ice for 30 minutes. The cells were then washed twice and resuspended in PBS. Data were acquired using a flow cytometer and analyzed using flow cytometry data processing software.
[0084] The preparation and treatment methods of nanoparticles in the following experiments are as follows: The materials used to prepare nanoparticle drugs were provided by Professor Dai Yunlu's laboratory. Polyethylene glycol and drugs were dissolved in methanol, and the mixture was added to a solution of deionized water / tetrahydrofuran and sonicated for 5 minutes. After removing the organic phase by vacuum suction, the unencapsulated components were filtered using a 220nm filter membrane, and the remaining solution was concentrated and stored in a dark bottle at 4°C. The morphology of the nanoparticles was studied by transmission electron microscopy, and the UV-visible absorption spectrum was measured using a spectrophotometer. 200 μL of RFP-labeled control polyethylene glycol was injected into tumor-bearing nude mice through the tail vein, and the enrichment of nanoparticles at the tumor site was observed using the IVIS Illumina in vivo system. When the average tumor size reached approximately 50 mm 3 , PEG containing drugs was injected three times through the tail vein, and the mice were killed on the 26th day.
[0085] The statistical analysis method for the data obtained in the following experiments is as follows: GraphPad Prism 8.0 (GraphPad Software, USA) was used for statistical analysis. Unpaired Student's t-test was used for comparison between two groups, and one-way analysis of variance (ANOVA) was used for comparison between multiple groups. Correlation analysis was performed using the Pearson correlation coefficient test. Data are expressed as mean ± SD from at least three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 were considered statistically significant compared with the control group.
[0086] Most breast cancers occur sporadically without a family history, but approximately 5-10% are heritable. Breast cancer-associated gene 1 (Brca1) is a tumor suppressor gene whose germline mutations lead to familial breast cancer. Brca1 has many important functions, including transcriptional regulation, DNA damage repair, centrosome duplication, cell cycle checkpoints, chromatin remodeling, and protein ubiquitination. Current studies have found that approximately 25% of Brca1-deficient mice develop mammary tumors by 1.5 years of age, and approximately 20% of these mice develop metastases to distant organs. Further studies have shown that Brca1 deficiency leads to numerous abnormalities in mammary gland development, such as blunted ductal morphogenesis, genome-wide gene expression dysregulation, enhanced DNA replication fork firing, and increased apoptosis; this is partially supported by loss of p53, Atm, Chk2, and 53PB1 function or activation of certain oncogenes. Breast cancer patients with Brca1 mutations also experience a high frequency of multi-organ metastasis. Therefore, the inventors believe that research on Brca1 mutations has important implications for the prevention and treatment of breast cancer and multi-organ metastasis.
[0087] The inventors first used immunofluorescence staining to label luminal epithelial cells (CK18), basal or myoepithelial cells (CK14), and basement membrane (collagen IV) in human breast cancer patients with or without Brca1 mutations and in the Brca1-MSK mouse model to detect the mammary gland's bilayer structure, consisting of a luminal layer and a basal layer surrounded by a basement membrane. The results are shown in Figure 1. The labels in the figure are: WT indicates non-BRCA1 mutation, and MT indicates BRCA1 mutation.
[0088] Figure 1A shows a representative image of a tumor-adjacent mammary gland from a breast cancer patient; Figure 1C shows a representative image of a tumor tissue from a breast cancer patient. CK18 / CK14 co-staining was used, and the percentage of affected basal layers in the tumor-adjacent mammary gland and tumor tissue was calculated, yielding the results shown in Figures 1B and 1D, respectively. Figures 1AD show that compared to non-BRCA1 mutation-positive breast cancer patients, the basal layer is severely depleted in both tumor-adjacent mammary gland and tumor tissue.
[0089] Figure 1E shows a representative image of a tumor-adjacent mammary gland from a Brca1-MSK mouse; Figure 1G shows a representative image of tumor tissue from a Brca1-MSK mouse. CK18 / Collagen IV co-staining was used, and the percentage of affected basal layers in the tumor-adjacent mammary glands and tumor tissues of the mice was calculated, yielding the results shown in Figures 1F and 1H, respectively. This also reveals that compared to non-BRCA1 mutant Brca1-MSK mice, the basal layer is severely lost in both tumor-adjacent mammary gland tissue and tumor tissue. This suggests that BRCA1-deficiency-related tumorigenesis has a greater impact on mammary gland structural integrity than sporadic tumorigenesis.
[0090] Furthermore, the inventors used immunofluorescence staining to study the structural integrity of the mammary glands of 8-month-old and 10-month-old non-mutated and mutant Brca1-MSK mice, all of which were in the stage before or at the beginning of tumor formation. As shown in Figure 1IK, the mammary gland structure of non-BRCA1 mutant mice was more complete, while the mammary gland structure of mice after BRCA1 mutation was abnormal. The experiment was further conducted on 10-month-old mice. Representative images of tumor-adjacent mammary tissue of 10-month-old non-mutated mice and control mice (shown in Figure 1L) were co-stained with CK18 and CK14, and the percentage of the destroyed basal layer was calculated (shown in Figure 1M). Representative images of tumor tissue of 10-month-old non-mutated mice and control mice (shown in Figure 1N) were co-stained with CK18 and CK14, and the percentage of the destroyed basal layer was calculated (shown in Figure 1O). As shown in Figure 1LO, the basal layer of 10-month-old mutant mice was severely missing and the mammary ducts were destroyed. These results suggest that Brca1 deficiency in mammary epithelial cells and mice leads to structural abnormalities before and during tumorigenesis.
[0091] Cancer metastasis is a highly complex process, with malignant cells undergoing epithelial-mesenchymal transition (EMT) prior to metastasis. Examination of tumor-adjacent breast tissue from breast cancer patients using a vimentin antibody revealed that higher levels of vimentin were detected in BRCA1. Furthermore, in the Brca1-MSK mouse model, mutation carriers exhibited more multi-organ metastases (Figure 2H) than non-mutation carriers (Figure 2DG).
[0092] By comparing the gene expression profiles of RNA sequencing analysis of age-matched Brca1 wild-type mammary tissue (WTMG), Brca1 mutant mammary tissue (MTMG), and Brca1 mutant primary tumors (MTPT), the results are shown in Figure 2. As shown in Figure 2, I, compared with the process from WTMG to mammary tumor tissue, EMT marker regulators, such as Ddr2 and Itga5, and EMT markers, such as vimentin, Fn1, MMP2, MMP3, MMP14, Tcf3, Twist, and Zeb2, continued to increase in the process from MTMG to mammary tumor tissue, while mammary epithelial differentiation markers, including Krt19, Krt18, Krt5, and Krt14, were significantly reduced in mammary tumor tissue from Brca1-MSK mice. These findings suggest that mammary epithelial cells in Brca1-MSK mice undergo a different change process than currently understood.
[0093] Furthermore, the inventors performed a cytokine array screening experiment using sera from 6-month-old non-Brca1 mutant (WT) and Brca1 mutant (Brca1-MSK) mice, and obtained the results shown in Figures 1 and 2 .
[0094] As shown in Figure 1P and Figure 2J, 34 differentially expressed cytokines were detected in the blood of Brca1-MSK mice compared to WT mice, including 20 increased cytokines and 14 decreased cytokines. Among them, the inventors found that sialic acid-binding receptors, such as soluble E-selectin (Sele), L-selectin (Sell), Vcam1, and Madcam1, were significantly increased in the blood of Brca1 mutant mice. This indicates that the interaction between sialic acid ligands on tumor cells of Brca1-MSK mice and receptors on endothelial cells and immune cells is increased.
[0095] Furthermore, real-time fluorescence quantitative PCR was used to examine G600 (Brca1-MT) and B477 (Brca1-WT) mammary epithelial cell lines. As shown in Figure 1 (Q), the mRNA levels of eight of these genes were significantly increased in G600 cells compared to B477 cells. As shown in Figures 2 (K-M), elevated mRNA levels of Sele, Sell, St8sia4, and St3gal1 were found in mammary tissue of Brca1-MSK mice compared to Brca1-WT mice. St8sia4 and St3gal1 mRNA levels were elevated in G600 mammary epithelial cells of Brca1-MT compared to the B477 cell line. Furthermore, referring to Figure 1 (R), which shows the protein levels of St8sia4 in the B477 control cell line and the Brca1-MT cell line, the inventors also demonstrated increased protein levels of the aforementioned genes using Western blot analysis, as shown in Figure 1 (QU). These experiments suggest that elevated levels of sialyltransferases St8sia4 and St3gal1, as well as the receptors for sialic acid ligands Sele and Sell, may lead to hypersialylation and alleviate the migration of malignant cells away from their original site.
[0096] The real-time fluorescence quantitative PCR method was used to detect the expression of the two genes St8sia4 and St3gal1 in B477 cells expressing the Brca1 knockdown plasmid (shBrca1) at different concentrations, and the results were shown in Figure 3. As can be seen from Figure 3A, both St8sia4 and St3gal1 are negatively regulated by Brca1. However, it is currently unclear whether acidic conditions exist in precancerous breast tissue and breast cancer tissue of patients carrying BRCA1 mutations. It is also unknown whether acidity, if present, will affect the breast integrity and cancer metastasis of these patients. Based on this, the inventors continue to propose the following solution.
[0097] The two genes, St8sia4 and St3gal1, are responsible for the production of polysialic acid (PSA) and Sialyl-Lewis A (sLeA), respectively. Polysialic acid (PSA) is a highly negatively charged polymer molecule that can lower the local pH value by charge attraction in the presence of polyanions on the cell membrane. The inventors used PSA antibodies to detect the levels of polysialic acid (PSA) in mammary epithelial cells of mice and humans with or without BRCA1 defects, and obtained the results shown in Figure 3. As can be seen from Figure 3 BE, Figure 3 BC is the test result of mice, specifically by IF staining, using PSA to quantify the PSA distribution pattern (Figure 3 B) and quantity (Figure 3 C) in normal mammary tissue (Figure 3 Ba), tumor-adjacent mammary tissue (Figure 3 Bb) and tumor epithelial cells (Figure 3 Bc) of 10-month-old Brca1-MSK mice. Figures 3, D and E show the results of human mammary epithelial cell testing. Specifically, PSA staining quantifies the distribution pattern (Figure 3, D) and quantity (Figure 3, E) of PSA in epithelial cells from breast cancer patients (n=4 BRCA1 mutation carriers and n=21 non-BRCA1 mutation carriers). PSA levels were elevated in mammary epithelial cells from both BRCA1-deficient mice and humans.
[0098] Furthermore, the inventors used a ratiometric fluorescence probe method to detect the pH values of mammary gland tissues of 8-month-old Brca1-MSK mice and WT mice of the same age, as well as tumors from Brca1-MSK and WT mice, and obtained color intensity ratios as shown in Figure 3F. As shown in Figures 3FG, the average pH values of mammary gland tissues and tumors of Brca1-MSK mice were 6.6 and 6.25, respectively, while the pH value of control mice was 7.4.
[0099] Furthermore, the inventors conducted tissue microarray analysis on 95 human breast cancer samples, obtaining the results shown in Figure 3. Breast cancer tissues were routinely stained with IHC or IF using BRCA1 antibodies and PSA (as shown in Figure 3H), and PSA was quantified in breast cancer patients with high, moderate, and low BRCA1 expression (as shown in Figure 3I). As shown in Figure 3HI, Brca1 expression is negatively correlated with PSA expression. Furthermore, as shown in Figure 4DF, no such correlation was detected between Brca1 and LDHA (Figures 4D-E) or between PSA and LDHA (Figure 4F), indicating that the acidic tumor microenvironment induced by BRCA1 deficiency or low expression is not caused by excessive lactate production.
[0100] Therefore, the inventors proposed a new method for neutralizing the acidic tumor microenvironment, which includes using a sialyltransferase inhibitor to neutralize the acidic tumor microenvironment.
[0101] Breast fat masses were implanted into B477 cells expressing OE-St8sia4 or G600 cells expressing sgSt8sia4, with blank controls provided. Changes in pH were examined, yielding the results shown in Figure 3. Tumor images in B477 cells without or with OE-St8sia4 are shown in Figure 3J, tumor section images using the ratiometric fluorescent probe are shown in Figure 3K, and interstitial pH values are shown in Figure 3L. As shown in Figures 3JL, the interstitial tissue in breast tumor tissue expressing OE-St8sia4 exhibited larger tumor volume and lower pH values compared to the parental tumor tissue. Conversely, tumor images in G600 cells without or with sgSt8sia4 are shown in Figure 3M, tumor section images using the ratiometric fluorescent probe are shown in Figure 3N, and interstitial pH values are shown in Figure 3O. As shown in Figure 3M, the tumor volume was smaller. At the same time, as shown in Figure 3 NO, expression of sgSt8sia4 in G600 cells increased the pH of the interstitial breast tissue from pH 6.5 to pH 7.0, indicating that elevated sialyltransferases in the breast tissue observed early may lead to acidosis. Further, as shown in Figure 4 A, St8sia4 mRNA expression in G600 cells in the absence or presence of Brca1 for 72 hours was detected by qPCR. As shown in Figure 4 B, representative images of MMTV-cNeu, FGFR2-S252-W, and FGFR2-S252-W / Brca1-MSK mouse mammary tissues were co-stained with PSA (green) and E-cadherin (red) and imaged on an LSM880 high-resolution microscope (n = 3 mice / group). As shown in Figure 4 C, higher St8sia4 expression in human breast cancer patients is associated with poorer survival outcomes in breast cancer patients.
[0102] The above experiments indicate that, in addition to the currently known production of acidic conditions in tumors mainly through cancer cell metabolic activities, such as lactate accumulation, the lack or insufficiency of BRCA1 leading to high sialylation associated with high levels of sialyltransferases in breast tissue can establish an acidic tumor microenvironment (ATPME) in precancerous and breast tumor tissues.
[0103] As shown in Figure 5A, St8sia4 was overexpressed in the Brca1-MT545 cell line with low metastatic ability and the EMT6 cell line with moderate metastatic ability, and the integrity of the adjacent mammary glands was examined on days 7, 14, and 26 of tumor growth. By co-staining with CK14 and CK18 antibodies, in the EMT6 mouse model, destroyed adjacent mammary gland structures were observed on day 14, and more basal and luminal layer damage could be detected on day 26. When the sialyltransferase inhibitor 3Fax-P-Neu5Ac (STi) was used, the damaged mammary gland structure could be restored, as shown in Figure 5B. Similarly, by IF staining of CK18 and CK14, representative images of tumor-adjacent mammary tissue of nude mice implanted with 545 and OE-St8sia4-545 cells in the fat pad (Figure 5C), PSA / E-cadherin and CK18 / CollagenIV (Figure 5D) and CK18 / vimentin (Figure 5E) of tumor tissue of OE-St8sia4-545 cells, the scale bar is 10μm. As shown in Figure 5CE, the same mammary gland structure damage phenotype and EMT state observed in the EMT6 cell line were also observed in the 545 mouse model. This shows that high sialylation induced by elevated St8sia4 may lead to the destruction of mammary gland structure and enhance the effect of mammary epithelial cells on EMT.
[0104] Furthermore, the inventors conducted experiments using two cell lines, 628W and 545. The 628W cell line has high metastatic potential and expresses higher levels of St8sia4 and St3gal1, while the 545 cell line has low metastatic potential and low levels of St8sia4 and St3gal1. As shown in Figure 5A and Figure 6B, St8sia4 and St3gal1 were first overexpressed in 545 cells, and then St8sia4 and St3gal1 were knocked out in 628W cells using sgSt8sia4 and St3gal1 expression. As shown in Figure 5F and Figure 6CD, the migration status of these cells was studied in vitro, by fat pad implantation, and by tail vein injection in vivo. As shown in Figure 6EF, the transwell migration assay detected significantly greater migration from 545 cells harboring OE-St8sia4 and St3gal1 compared to the parental 545 cells, suggesting that cell morphology may change when St8sia4 and St3gal1 are overexpressed.
[0105] As shown in Figure 6, GJ, compared with the parental cells in 2D culture, EMT6 with OE-St8sia4 acquired EMT characteristics, while EMT6 and B477 cells with OE-St8sia4 acquired invasive characteristics in 3D culture.
[0106] In mammary fat pad implantation experiments, as shown in Figure 5G, overexpression of St8sia4 or St3gal1 in 545 cells promoted tumor growth. As shown in Figure 5H, stronger GFP metastasis signals were detected in the lungs of cells harboring OE-St8sia4, but not OE-St3gal1. In contrast, as shown in Figure 5JK, in tail vein injection experiments, stronger GFP metastasis signals were detected in the lungs of 545 cells after injection with OE-St3gal1 than with OE-St8sia4. These observations suggest that hypersialylation induced by St8sia4 and St3gal1 plays distinct roles at different steps in tumor metastasis. Similar pronounced effects on cancer metastasis were observed in 628W cells harboring sgSt8sia4 or sgSt3gal1, depending on their injection site. Although sgSt8sia4 blocked tumor metastasis only when 628W-sgSt8sia4 cells were injected into the fat pad but not into the tail vein, knocking out St3gal1 in 628W cells blocked tumor metastasis when the cells were injected at both sites, as shown in Figure 5, LO, and Figure 6, KL. These data suggest that polysialic acid (PSA) accumulation induced by elevated St8sia4 primarily establishes an acidic premetastatic niche at the primary tumor site, allowing malignant cells to ease their entry into the vasculature from damaged mammary gland structures, while elevated St3gal1 enhances tumor cell entry into distant organs of cancer metastasis during the circulation and extravasation steps, as shown in Figure 5, P.
[0107] Furthermore, histological analysis of tumor tissues derived from an allograft mouse model initiated with Brca1-MT cells revealed extensive angiogenesis in the tumor tissues by staining with antibodies to CD31 and endothelial mucin (Endomucin) in Figure 8, A. This observation was further supported by increased mRNA levels (Figure 8, B) and protein levels (Figure 8, C) of Vegfa and Il6 in luminal subpopulations sorted by Cd24 and Cd29 in GFP-positive cells from Brca1-MSK mice, suggesting that Brca1 deficiency may trigger increased expression of these oncogenes in mutant cells before tumor formation.
[0108] In addition, by monitoring the expression of Vegfa and Il6 in shBrca1-B477 cells and OE-Brca1-G600 cells, it was found that the mRNA levels of Vegfa and Il6 increased with shBrca1 transfection into B477WT cells (Figure 7A) and decreased in Brca1-MTG600 cells harboring OE-Brca1 cDNA (Figure 7B). As shown in Figures 7, CD, higher promoter activity of Vegfa and Il6 was observed in G600 cells compared with B477 cells. When mBrca1 was expressed in both cell types, their activities were inhibited, indicating that Brca1 negatively regulates the expression of Vegfa and Il6.
[0109] The protein levels of St8sia4 and St3gal1 were measured in B477 cells expressing shBrca1, shBrca1 / sgVegfa, and shBrca1 / sgIl6, as well as in G600 cells harboring OE-mBrca1, OE-Brca1 / OE-Vegfa, and OE-Brca1 / OEIl6, yielding the results shown in Figures 7 and 8. The data showed that in B477 cells expressing shBrca1 alone, the protein levels of St8sia4 and St3gal1 increased, but this increase was reversed by co-expression of sgVegfa or sgIl6 (as shown in Figure 7E). On the other hand, the inhibition of St8sia4 by OE-Brca1 in G600 cells was partially relieved by the expression of OE-Vegfa or OE-Il6 (as shown in Figure 7F). These data indicate that Brca1 negatively regulates St8sia4 and St3gal1 through Vegfa / Il6.
[0110] Vegfa and VegfIL6 are both transcriptional regulators involved in angiogenesis and tumor cell invasion, and Vegfa signaling can stimulate the production of TGF-β in A549 cells. Therefore, the inventors used protein immunoblotting to conduct experiments and found that the protein levels of Vegfa and VegfIl6 increased compared with the control group, and the levels of TGF-β1 and its downstream proteins pSmad3 / total-Smad3 and pStat3 / totalStat3 in the precancerous mammary glands (G in FIG. 7 ) and tumor tissues (H in FIG. 7 ) of Brca1-MSK mice were increased. In addition, the inventors also found that there is a positive mutual regulatory cycle between Vegfa and VegfIl6, that is, overexpression (OE) or knockout (KO) of either one of them may affect the other (as shown in FIG. 7 I). Thus, OE-Vegfa or OE-Il6 in G477 cells increased their own expression along with TGF-β, St8sia4, and St3gal1, whereas KO of Vegfa or Il6 reduced the expression levels of all these cells (as shown in Figure 7, I). Similar results were obtained in EMT6 and MDA-MB-231 cells (as shown in Figure 8, DE).
[0111] Furthermore, after treatment with TGF-β and its inhibitors in G600, the mRNA expression of epithelial cells, RAW264.7 cells, and SVEC4-10 cells and the displacement of polysialic acid (PSA) and S-selectin (Sele) on the cell membrane were detected. The data showed that TGF-β could induce the expression of St8sia4 and St3gal1 and other sialyltransferases in WT and Brca1-MT cells (as shown in Figure 7 J and Figure 8 FG), and after treatment with TGF-β inhibitors, the protein levels of St8sia4 and St3gal1 decreased (as shown in Figure 7 K). After treatment with TGF-β inhibitors or introduction of mBrca1 cDNA into G600 cells (as shown in Figure 7 LM) and SVEC4010 cells (as shown in Figure 8 HI), the displacement of PSA and Sele on the cell membrane was significantly increased and decreased. Consistent with the above analysis, knockout of Vegfa or VegfIl6 in 628W and G600 cells reduced the protein levels of St8sia4 and St3gal1 (as shown in Figure 8 J) and the production of polysialic acid PSA (as shown in Figure 8 LM). In contrast, overexpression of Vegfa or VegfIl6 in B477 cells increased the content of St8sia4 and St3gal1 (as shown in Figure 8 K). In nude mice implanted with G600 cells expressing sgVegfa or sgVegfIl6, tumor volume was reduced (as shown in Figure 7 NO) and the metastatic signal of green fluorescent protein GFP was inhibited (as shown in Figure 8 PR). There was also a positive correlation between TGF-β and St8sia4, VegfIL6 and St3gal1, and St3gal1 and Vegfa.
[0112] The spread of cancer cells requires the joint support of the tumor immunosuppressive microenvironment (TIME) from the original lesion and distant metastatic organs. The inventors used antibodies to CD45, CD11b, Ly6G and Ly6C, CD3, CD4 and CD8 to analyze various immune cell populations from mammary tissue in Brca1-MSK mice, as well as mammary tumor tissue transplanted with EMT6 parental cells, OE-St8sia4 cells, and OE-St8sia4 / sgSt8sia4 cells. Mass spectrometry flow cytometry was performed on days 14 and 26 after implantation, and the results of AB in Figure 9 were obtained. The data showed that compared with normal mammary tissue, the parental tumor accumulated more polymorphonuclear myeloid-derived suppressor cells (PMN-MDSC) and mononuclear myeloid-derived suppressor cells (M-MDSC), and reduced CD3+ and CD4+ cells. OE-St8sia4 in primary tumors significantly enhanced this phenotype, whereas sgSt8sia4 reversed it when analyzed on days 14 and 26.
[0113] Immunohistochemistry and IF staining were performed in the spleen and breast tumor tissues of the OE-St8sia4-EMT6 and OE-St8sia4-545 allogeneic transplant mouse models, where the MDSCs antibody was Gr1 (Ly6G and Ly6C), the M1-like macrophage antibody was F4 / 80 and CD86, and the M2-like macrophage antibody was F4 / 80 and CD206. As shown in Figures 10A-C, MDSCs increased in the spleen of Brca1-MSK mice. In the tumor tissues of the OE-St8sia4-EMT6 and OE-St8sia4-545 mouse models, M1-like macrophages decreased and M2-like macrophages increased (Figure 9 CE and Figure 10 DF). Compared with control mice, FACS flow cytometric analysis revealed the GI in Figure 10 . The above phenotype was also observed in Brca1-MSK mice at different ages and in different organs, which is because Brca1 negatively regulates the expression of St8sia4.
[0114] By detecting the MDSC population, immunohistochemistry using the S100a9 antibody, and flow cytometry analysis of Cd11b and Ly6G in spleen and tumor tissues expressing sgVegfa or sgVegfIl6, we found that MDSCs were reduced in tumor tissues (as shown in Figure 9, FG), increased in the spleens of OE-St8sia4-545 tumor-bearing mice, and reduced in the spleens of 628W tumor-bearing mice expressing sgSt8sia4 (Figure 9, H-I). This view was further supported by the reduction of MDSCs in spleen and breast tumor tissues expressing sgVegfa or sgVegfIl6 by flow cytometry analysis, as shown in Figure 10, J-L.
[0115] The inventors further analyzed bulk RNA-seq from bones, blood, spleen, and peritoneum of WT mice, Brca1-MSK mice without tumors, and Brca1-MSK mice carrying primary breast tumors, and then compared the expression patterns obtained in the TCGA database. In the Brca1-MSK mouse model, consistent with the above analysis, B cells, T cells, and dendritic cells (DCs) began to decrease, while immune cells from the myeloid cell lineage began to increase in the blood and spleen of Brca1 mutant mice without tumors and further increased in Brca1 mutant tumor-bearing mice (M in Figure 10). Gene expression of immune cells further illustrates the increase in macrophages and monocytes in bones, blood, and spleen, especially in the peritoneum of Brca1-MSK compared with WT mice (N in Figure 10). The characteristic gene expression pattern in immune cells showed highly expressed immunosuppressive genes, including TGF-β1, Smad3, Mmp9, Arg1, Arg2, Il10, Il1β and PD-L1 in the blood, spleen and peritoneum (O in Figure 10), indicating that Brca1 deficiency leads to a stronger immunosuppressive environment in those organs. The above gene expression analysis was further supported by the increased levels of TGF-β signaling proteins by Western blotting (P in Figure 10). Correlation analysis of st8sia4 and St3gal1 expression with immune cell populations in the TCGA database showed that St8sia4 expression was positively correlated with MDSCs, macrophages and Treg cells (JN in Figure 9), but was not related to St3gal1. These data indicate that elevated St8sia4, Vegfa / Il6 and Brca1 deficiency reshape the tumor immunosuppressive microenvironment that may be conducive to tumor cell growth and metastasis.
[0116] Since the acidic tumor microenvironment (ATPME) induced by high sialylation may damage the structure of the mammary bilayer, it promotes the entry of malignant cells into blood vessels through the extracellular matrix (ECM). The inventors next studied whether the neutralization of ATPME could inhibit tumor metastasis. 3Fax-P-Neu5Ac (STi) is a highly acetylated analog of naturally occurring Neu5Ac that inhibits sialyltransferase function. Another drug selected is Stattic, an inhibitor that can disrupt TGF-β signaling induced by pStat3 and pSmad3 activation, because the levels of proteins pStat3 and pSmad3 are increased in cells with low Brca1 expression or high Vegfa / Il6 expression. First, these two drugs were used for monotherapy and combination therapy in allogeneic transplanted tumors generated by 628W cells by intraperitoneal injection (as shown in Figure 12A). The data showed that intraperitoneal injection of STi (20 mg / kg) or Stattic (10 mg / kg) for single treatment can inhibit primary tumor growth (as shown in Figure 12 BC) and GFP metastasis signals in the lungs (as shown in Figure 12 DE) to a certain extent, while reducing lung weight (as shown in Figure 12 F). The combination of these two drugs further reduced tumor growth (as shown in Figure 12 BC) and reduced metastasis signals in the lungs (as shown in Figure 12 DE), indicating that neutralizing the acidic environment and inhibiting TGF-β signaling can synergistically delay the growth of primary tumors and block the metastasis that reverses the splenomegaly phenotype. Moreover, using H&E staining, no obvious cytotoxic effects were observed in the lungs, kidneys, liver, or spleen (as shown in Figure 12 F).
[0117] Currently, although an effective dose (25 mg / kg) of 3Fax-P-Neu5Ac can inhibit the growth of myeloma tumors, it also causes edema in the peritoneal cavity of mice and toxicity to the liver and kidneys. Due to the potential side effects of these anticancer drugs, the inventors packaged the drug into nanoparticles with amphiphilic polymers and administered it three times by intravenous injection every three days when the tumor size reached approximately 50 mm3 after implantation (Figure 11A). The data showed that nanoparticles can be enriched in mammary tissue 48 hours after tail vein injection (Figure 11B). Nanoparticles containing Stattic or STi significantly reduced primary tumor growth and GFP metastasis signals (CF of Figure 11).
[0118] Furthermore, the pH value of tumor tissue was measured in the same group of mice by using a ratiometric fluorescent probe. The ratio of green to red was much larger in the control group (PBS and PEG treatment groups) compared with the drug treatment group (Figure 11GH) and after treatment with Stattic or STi, the pH value of mammary tissue recovered from approximately 6.5 to 6.8 to above 7.0 (Figure 10H).
[0119] Further, the inventors used STi, Stattic or double treatment with STi and Stattic, and co-stained tumors and tumor-adjacent mammary glands with CK18 / Collagen IV or CK18 / CK14 antibodies. The HJ data of Figure 11 show that when treated with a single or combined drug, more collagen bundles were formed in the tumor tissue detected by CK18 / collagen IV staining in the mammary basement membrane compared to the parent control tumor tissue (D of Figure 11), which can prevent tumor cells from escaping from their original position; by double staining (J of Figure 11) with CK14 and CK18 antibodies, after treatment with a single drug or two drugs together, more mammary ducts with a complete basal cell layer were observed (IJ of Figure 11), indicating that the acidic conditions in the mammary tissue caused by high sialylation can be specifically neutralized by nanoparticles containing pan-inhibitors of sialyltransferases and inhibitors of TGF-β signaling molecules.
[0120] Immunotherapy resistance is a very challenging problem in the treatment of cancer patients. As shown in the above experiments, increased expression of St8sia4 reduces effector T cells and accumulates MDSCs in mammary tissue. The inventors first examined the expression levels of PD1, CD3, PD-L1, and CK18 in the mammary tissue of Brca1-MSK mice implanted with parental EMT6 cells and EMT6 / OE-St8sia4 cells. Very weak and abnormal expression of PD-1 and CD3 was detected in tumors initiated by EMT6 parental cells. CD3-positive cells were significantly reduced, accompanied by the clear appearance of PD-1-positive immune cells in mammary tumor tissues by OE-St8sia4 for 7 days (Figure 13A), while very strong PD-L1-St8sia4 was detected in control parental tumors and OE tumors for 7 days (Figure 13B), indicating that OE-St8sia4-induced ATPME triggered T cell death.
[0121] Because polysialic acid (PSA) is a highly negatively charged polymer molecule, mice bearing tumors overexpressing St8sia4 were treated with αPD-1, STiNPs, and STiNPs combined with αPD-1 (Figure 14A). The data showed that OE-St8sia4 promoted tumor growth, treatment with αPD1 alone did not change tumor growth at all, and treatment with sialyltransferase inhibitor nanoparticles (STiNPs) alone significantly reduced tumor growth. However, the combination of STi and αPD-1 further inhibited tumor growth compared to parental tumors, tumors with OE-St8sia4, and tumors treated with αPD-1 alone (Figure 13C-D). The splenomegaly phenotype was also reversed in the STi and αPD-1 combined treatment groups (Figure 14B and Figure 13E, respectively), while liver weight did not change significantly (Figure 14CD).
[0122] To further examine the changes in MDSC, Cd4+ and Cd8+ cell populations in tumor tissues before and after OE-St8sia4 treatment, mass spectrometry flow cytometry analysis was performed to support the above viewpoints. The data showed that 1) OE-St8sia4 reduced Cd4+ and Cd8+ cell populations and increased M-MDSCs and PMN-MDSCs; 2) there was no significant change in the immune population after αPD-1 monotherapy compared with the control group; 3) 3Fax-P-Neu5Ac (STi) monotherapy restored the Cd4+ and Cd8+ populations and reduced the populations of M-MDSCs and PMN-MDSCs; 4) in the αPD-1 and 3Fax-P-Neu5Ac combination treatment group, the Cd4+ and Cd8+ populations continued to increase, and the populations of M-MDSCs and PMN-MDSCs were much less than those in the αPD-1 or 3Fax-P-Neu5Ac single treatment groups, as shown in Figure 13F and Figure 14E), indicating that MDSCs were reduced and T cells were increased after STi-αPD-1 combination treatment.
[0123] Consistent with mass spectrometry analysis, the levels of CD3-positive cells and Caspase3 protein increased and the levels of polysialic acid decreased in the 3Fax-P-Neu5Ac and 3Fax-P-Neu5Ac+αPD-1 treatment groups (Figure 13, GH). H&E staining also showed that the lung morphology of metastatic lungs was restored in the 3Fax-P-Neu5Ac and 3Fax-P-Neu5Ac+αPD-1 treatment groups, and there was no obvious toxic effect on other organs including the liver and spleen before and after treatment, as shown in Figure 13, H and Figure 14, D. In summary, these data indicate that ATPME caused by OE-St8sia4 is associated with resistance to immunotherapy, and the combination of 3Fax-P-Neu5Ac and αPD-1 sensitizes breast tumors with ATPME to αPD-1 treatment.
[0124] In summary, the inventors' research has determined that breast cancer caused by Brca1 deficiency has a sialyltransferase-mediated mechanism that can induce an acidic tumor microenvironment (ATPME) in Brca1 mutant and most Brca1-low-expressing breast cancers, and that hypersialylation caused by polysialic acid (PSA) damages the bilayer structure of the mammary epithelium and establishes an acidic tumor microenvironment (ATPME) and a tumor immunosuppressive microenvironment (TIME) that contribute to cancer metastasis. In addition, the carcinogenic effect of Vegfa / Il6 induced by Brca1 deficiency or insufficiency activates TGFβ-St8sia4 signaling, increases the accumulation of polysialic acid on the mammary epithelial membrane, and forms a malignant niche that promotes cell evasion of immune surveillance, ultimately leading to tumor metastasis and resistance to αPD-1 therapy. Therefore, the inventors proposed the use of sialyltransferase inhibitors to prevent or treat breast cancer caused by Brca1 deficiency. By using sialyltransferase inhibitors, the expression of sialyltransferase is reduced, neutralizing the acidic tumor microenvironment formed, thereby achieving the effect of treating or even reversing the basement membrane defects of breast epithelial cells. In addition, by combining sialyltransferase inhibitors with drugs such as PD-1 or Stattic, ATPME can be further neutralized and tumor growth and metastasis can be blocked, greatly reducing the chance of tumor metastasis.
[0125] The foregoing description is merely a preferred embodiment of the present disclosure and is not intended to limit the present disclosure. Those skilled in the art will readily appreciate that various modifications and variations are possible. Any modifications, equivalent substitutions, or improvements made within the spirit and principles of the present disclosure shall be included within the scope of protection of the present disclosure. Industrial Applicability
[0126] The present disclosure provides the use of a sialyltransferase inhibitor in the preparation of a medicament for neutralizing an acidic tumor microenvironment, relating to the technical field of tumor treatment. The present disclosure provides the use of a sialyltransferase inhibitor in the preparation of a medicament for neutralizing an acidic tumor microenvironment. The sialyltransferase inhibitor can neutralize the acidic tumor microenvironment and establish an ecological barrier to tumor metastasis, providing a new approach for tumor prevention and treatment and possessing excellent industrial applicability.
Claims
1. Use of a sialyltransferase inhibitor in the preparation of a drug for neutralizing an acidic tumor microenvironment.
2. The use according to claim 1, characterized in that: The sialyltransferase inhibitor neutralizes the acidic tumor microenvironment by downregulating the expression of Vegfa and / or VegfIl6.
3. The use according to claim 1, characterized in that: The sialyltransferase inhibitor includes at least one of 3Fax-Peracetyl Neu5Ac or Stattic.
4. The use according to claim 1, characterized in that: The sialyltransferase inhibitor inhibits the expression of polysialyltransferase and / or polysialyltransferase receptor.
5. The use according to claim 4, characterized in that: The polysialyltransferase includes St8sia4.
6. The use according to claim 4, characterized in that: The polysialyltransferase receptor includes at least one of soluble E-selectin and L-selectin.
7. The use according to any one of claims 2 to 6, characterized in that: The drug for neutralizing the acidic tumor microenvironment also includes a PD-1 drug; optionally, the PD-1 drug is a PD-1 antibody.
8. Use of a sialyltransferase inhibitor in the preparation of a drug for treating Brca1 defect-related tumors; Preferably, the drug for treating Brca1 deficiency-related tumors also includes a PD-1 drug; optionally, the PD-1 drug is a PD-1 antibody; Optionally, the Brca1 deficiency-associated tumor is Brca1 deficiency-associated breast cancer.
9. Use of a sialyltransferase inhibitor in the preparation of a drug for preventing or treating cancer, characterized in that: The drug for preventing or treating cancer includes drugs for preventing or treating any one of the occurrence, metastasis or growth of cancer; Optionally, the drug for preventing or treating cancer further includes a PD-1 drug; optionally, the PD-1 drug is a PD-1 antibody; Optionally, the cancer includes any one of breast cancer, liver cancer, and spleen cancer.
10. Use of a sialyltransferase inhibitor in the preparation of a drug for treating damage to the double-layer structure of mammary epithelium; Optionally, the drug for treating destruction of the double-layer structure of mammary epithelium also includes a PD-1 drug; optionally, the PD-1 drug is a PD-1 antibody.
11. A pharmaceutical composition comprising a sialyltransferase inhibitor and a pharmaceutically acceptable carrier; Optionally, the sialyltransferase inhibitor comprises at least one of 3Fax-Peracetyl Neu5Ac or Stattic; Optionally, the dosage form of the drug includes any one of injection, injection, tablet, granule, granule or capsule; Optionally, the drug is in the form of nanoparticles.
12. A method for neutralizing an acidic tumor microenvironment, the method comprising administering to a subject in need thereof an effective amount of a sialyltransferase inhibitor.
13. A method for treating a tumor associated with Brca1 deficiency, the method comprising administering to a subject in need thereof an effective amount of a sialyltransferase inhibitor; Optionally, the Brca1 deficiency-associated tumor is Brca1 deficiency-associated breast cancer.
14. A method for preventing or treating cancer, comprising administering an effective amount of a sialyltransferase inhibitor to a subject in need thereof; wherein: Drugs for preventing or treating cancer include drugs for preventing or treating any of the occurrence, metastasis or growth of cancer; Optionally, the cancer includes any one of breast cancer, liver cancer, and spleen cancer.
15. A method for treating disruption of the bilayer structure of mammary epithelium, the method comprising administering to a subject in need thereof an effective amount of a sialyltransferase inhibitor.
16. The method according to any one of claims 12 to 15, wherein: The sialyltransferase inhibitor comprises at least one of 3Fax-Peracetyl Neu5Ac or Stattic; Optionally, the method comprises the combined use of a PD-1 drug; optionally, the PD-1 drug is a PD-1 antibody.
17. A sialyltransferase inhibitor for use in: i. Neutralize the acidic tumor microenvironment; ii. Treating Brca1 deficiency-related tumors; optionally, the Brca1 deficiency-related tumor is Brca1 deficiency-related breast cancer; iii. prevention or treatment of cancer; wherein, Preventing or treating cancer includes preventing or treating any one of the occurrence, metastasis or growth of cancer; optionally, the cancer includes any one of breast cancer, liver cancer and spleen cancer; iv. Treat the destruction of the double-layer structure of mammary epithelium.
18. The sialyltransferase inhibitor according to claim 17, wherein The sialyltransferase inhibitor includes at least one of 3Fax-Peracetyl Neu5Ac or Stattic; Optionally, the use includes a sialyltransferase inhibitor combined with a PD-1 drug; optionally, the PD-1 drug is a PD-1 antibody.
Citation Information
Patent Citations
Sialyltransferase inhibitors and uses thereof
CN108026138A
Application of pathways for inhibiting induction of IFN-I (interferon-I) to ARG1 (arginase 1) to preparing antitumor pharmaceutical compositions
CN109364252A
Application of sialyltransferase inhibitor in preparation of medicine for neutralizing acid tumor microenvironment
CN116549646A
New potent sialyltransferase inhibitors
US20210107931A1
Method for treatment of cancer
US20210186999A1
